Verified Document

Pharmaceutical Companies And Physicians Appropriate Relationships Research Paper

Related Topics:

Pharmaceutical Companies and Physicians: A Discussion The power of pharmaceutical companies cannot and should not be underestimated in any manner. Their power is immense as is their influence and more consumers need to understand how they constantly shape the industries of health, medicine and wellness. However, it’s important to acknowledge the intensity of the connection between doctors and pharmaceutical companies. This is a connection that begins when doctors are in medical school—they are subjected to a barrage of gifts, meals, trinkets and drug samples that starts early and continues on throughout their professional careers (Kshirsagar &Vu, 2016). Clearly this rapport creates a conflict of interest that can be damaging to the healthcare system. In order to protect themselves, consumers and citizens everywhere should demand a greater level of transparency in regards to how doctors are being compensated among other things. This paper will discuss in depth the necessity for a higher level of transparency in this regard and how this will directly benefit both the individual and society.

Federal legislation requiring a disclosure of payments made to physicians should be mandatory. It is crucial for citizens to know the amount and extent that doctors are being compensated by these pharmaceutical companies. However, it can’t simply be dollar amounts that are revealed. Pharmaceutical companies are incredibly sneaky and would likely find ways to evade...

For example, they might start sending doctors more expensive gifts such as vacations, cars, donations made to their children’s schools, bricks of gold, cash gifts that can evade reporting, or paying for repairs/renovations on physicians’ homes. Federal legislation needs to be rigorous and state that every single gift or financial token or assistance the doctors receive from pharmaceutical companies must be reported.
Federal law should be as rigorous as humanly possible in this regards, but states should absolutely have the freedom to engage in more comprehensive requirements, if they so desire. As our textbook states “Vermont, for example, now bans most gifts to physicians, while requiring disclosure of payments for speaking, consulting, and research” (Burns et al., 2011). This is crucial as Vermont was one of the states that was hit most hard with the opioid crisis. It is unclear to what extent that unhealthy and somewhat corrupt pharmaceutical company-physician connection contributed to this crisis—just that it did. Thus, if states in the union want to create the most stringent and severe requirements in this regard with the harshest penalties for violation, they are well within their rights to do so. Doing so will likely be beneficial for the rest of the nation as it will set a good example for other states. It will ultimately demonstrate what an appropriate relationship does and does…

Cite this Document:
Copy Bibliography Citation

Related Documents

Ethical Issues Arising From Doctors Relationships With Drug Companies...
Words: 1528 Length: 5 Document Type: Essay

Doctors Drugs Although the Affordable Health Care Act represents a step in the right direction towards encouraging all Americans to avail themselves of medical services, the bill fails to address the root causes of problems in the system. The American health care system is flawed because it is a for-profit model that places profits far ahead of patients. When profits come ahead of patients, the result is an inability to fulfill

Drug Company Perks As a
Words: 657 Length: 2 Document Type: Article Critique

Patients have a right to know if their doctor's decision to prescribe a certain medication has been influenced by free lunches or other perks, rather than that doctor's objective overview of prescribing information. In fact, the real ethical issue presented in the underlying case is not that the doctors are accepting gifts from the pharmaceutical companies. Drug companies did decide to some degree of self-limit in their gifts to physicians.

Market Driven Management
Words: 25695 Length: 75 Document Type: Term Paper

Pharmaceutical industries have to operate in an environment that is highly competitive and subject to a wide variety of internal and external constraints. In recent times, there has been an increasing trend to reduce the cost of operation while competing with other companies that manufacture products that treat similar afflictions and ailments. The complexities in drug research and development and regulations have created an industry that is subject to intense

Direct to Consumer Advertising History of Drug
Words: 16271 Length: 59 Document Type: Term Paper

Direct to Consumer Advertising HISTORY OF DRUG ADVERTISING THE DTC ADVERTISING PHENOMENON CREATING DEMAND DECEPTIVE ADVERTISING - A WOLF IN SHEEP'S CLOTHING CAUSE OF DEATH PROFIT UTILIZATION, PRICING, AND DEMOGRAPHICS LEGISLATION, POLITICS AND PATENTS LEGISLATIVE INITIATIVES REGARDING DTC RECALLED and/or DEADLY DRUGS In order to provide the most efficient method of evaluation, the study will utilize existing stores of qualitative and quantitative data from reliable sources, such as U.S. Government statistical references, University studies, and the studies and publications of non-profit

Educational Leadership
Words: 2034 Length: 8 Document Type: Term Paper

Marketing Success of Pfizer Pharmaceutical Company Pfizer is undeniably the most successful pharmaceutical company in existence. It rated first in U.S. sales from April 2002 through March 2003, with a total sales number of $20 billion USD, which accounted for 10% of the market share, and 12% growth. It ranked #1 ahead of GlaxoSmithKline, Johnson & Johnson, and Merck & Co., which took the second, third, and fourth spots, respectively.

Ethical Analysis of Merck and Vioxx
Words: 3984 Length: 11 Document Type: Essay

Ethical Analysis of Merck and Vioxx How could Merck management have handled the research, development and marketing of Vioxx in a more ethically responsible fashion, if at all? On September 30, 2004, Merck & Company declared the drawback associated with Vioxx, its extremely profitable pain reducer for osteoarthritis victims, from the marketplace. This particular move came only 7 days after scientists within the company discovered in a medical trial that subjects who

Sign Up for Unlimited Study Help

Our semester plans gives you unlimited, unrestricted access to our entire library of resources —writing tools, guides, example essays, tutorials, class notes, and more.

Get Started Now